biostudies-literatureUnknown33(9)Lopez-Chavez AIntramural NIH HHS<h4>Purpose</h4>We conducted a basket clinical trial to assess the feasibility of such a design strategy and to independently evaluate the effects of multiple targeted agents against specific molecular aberrations in multiple histologic subtypes concurrently.<h4>Patients and methods</h4>We enrolled patients with advanced non-small-cell lung cancer (NSCLC), small-cell lung cancer, and thymic malignancies who underwent genomic characterization of oncogenic drivers. Patients were enrolled onto a not-otherwise-specified arm and treated with standard-of-care therapies or one of the following five biomarker-matched treatment groups: erlotinib for EGFR mutations; selumetinib for KRAS, NRAS, HRAS, or BRAF mutations; MK2206 for PIK3CA, AKT, or PTEN mutations; lapatinib for ERBB2 mutations or amplifJournal of clinical oncology : official journal of the American Society of Clinical Oncology1000-7https://www.ebi.ac.uk/biostudies/studies/S-EPMC4356709biostudies-literatureMolecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.PMC4356709Kelly RRajan ACorless CLCarter CAThomas AMeltzer PSKillian KSteinberg SMWarrick ARaffeld MXi LLopez-Chavez AWang YMorrow BSandler ALiewehr DJGiaccone GPack SDoyle ABeadling CGuha UBerman ASzabo ELau CCAbdullaev ZfalseMolecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.<h4>Purpose</h4>We conducted a basket clinical trial to assess the feasibility of such a design strategy and to independently evaluate the effects of multiple targeted agents against specific molecular aberrations in multiple histologic subtypes concurrently.<h4>Patients and methods</h4>We enrolled patients with advanced non-small-cell lung cancer (NSCLC), small-cell lung cancer, and thymic malignancies who underwent genomic characterization of oncogenic drivers. Patients were enrolled onto a not-otherwise-specified arm and treated with standard-of-care therapies or one of the following five biomarker-matched treatment groups: erlotinib for EGFR mutations; selumetinib for KRAS, NRAS, HRAS, or BRAF mutations; MK2206 for PIK3CA, AKT, or PTEN mutations; lapatinib for ERBB2 mutations or amplif2015-01-01T00:00:00Z2015 Mar2026-05-03T14:28:22.939Z2019-03-27T01:48:02ZS-EPMC43567092566727410.1200/JCO.2014.58.200710.1200/jco.2014.58.2007